| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to compounds of formula (I) where R 1 is chosen from a group consisting of phenyl, unsubstituted or substituted by one or two groups independently chosen from (lower) alkyl, (lower) phenylalkyl wherein a phenyl ring can be unsubstituted or substituted by one or two groups independently chosen from halogen; R 2 represents hydrogen; or R 1 and R 2 together with nitrogen atom whereto attached, form a saturated 5- or 6-members heterocyclic ring optionally containing an additional oxygen heteroatom, said saturated heterocyclic ring is unsubstituted or substituted by one, two or three groups independently chosen from (lower) alkyl, halogen; R 3 is chosen from a group consisting of hydrogen, (lower) alkyl, (lower) hydroxyalkyl, (lower) alkoxyalkyl, (lower) haloalkyl, (lower) cycloalkylalkyl, (lower) cyanoalkyl, (lower) alkylsulfonyl, phenyl unsubstituted or substituted by one or two groups independently chosen from halogen; R 4 represents hydrogen or halogen; R 5 represents a group chosen from where m represents 0 or 1; n represents 0,1 or 2; X represents CR 13 R 13' ; R 6 , R 6' , R 7 , R 7' , R 8 ,R 8' , R 13 , R 13' are independently chosen from a group consisting of hydrogen, (lower) alkyl, halogen; p represents 0 or 1; R 9 is chosen from (lower) alkyl, cycloalkyl, (lower) cycloalkylalkyl; q represents 0 or 1; R 10 represents (lower) alkyl; and to their pharmaceutically acceptable salts, as well as to a pharmaceutical composition exhibiting histamine 3 receptor antagonistic and/or antagonistic activity and based on the compounds of formula I. n EFFECT: there are prepared and described new compounds which can be effective in treatment and/or prevention of the diseases associated with H3 receptor modulation. n 24 cl, 34 ex |